Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase I/II trial for Patients with Low and Intermediate-Risk Prostate Cancer
This study presents a prospective phase I, IRB-approved dose-escalated stereotactic body radiotherapy (SBRT) trial for prostate cancer (CaP) to assess the impact of dose level on quality of life, toxicity, and clinical outcomes.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Louis Potters, Zaker Rana, Lucille Lee, Brett W. Cox Tags: Clinical Investigation Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Physics | Prostate Cancer | Radiology | Study | Toxicology